Compare MBBC & IXHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | MBBC | IXHL |
|---|---|---|
| Founded | 1902 | 2001 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.1M | 35.4M |
| IPO Year | 2020 | 2024 |
| Metric | MBBC | IXHL |
|---|---|---|
| Price | $14.67 | $2.68 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 2.2K | ★ 54.3K |
| Earning Date | 11-11-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 3200.00 | N/A |
| EPS | ★ 0.66 | N/A |
| Revenue | N/A | ★ $12,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $21.97 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.53 | $0.16 |
| 52 Week High | $15.79 | $6.39 |
| Indicator | MBBC | IXHL |
|---|---|---|
| Relative Strength Index (RSI) | 37.43 | 29.84 |
| Support Level | $14.16 | $2.49 |
| Resistance Level | $15.39 | $3.89 |
| Average True Range (ATR) | 0.14 | 0.13 |
| MACD | -0.06 | -0.04 |
| Stochastic Oscillator | 36.13 | 14.00 |
Marathon Bancorp Inc is a mid-tier holding company for Marathon Bank, a Wisconsin-chartered savings bank. The group operates as a community-oriented bank offering a variety of financial products and services to meet the needs of customers. The primary deposit products are demand deposits, savings, and certificates of deposits; and prime lending products are commercial real estate, commercial and industrial, construction, one-to-four-family residential, multifamily real estate, and consumer loans. The majority of the group's revenue comes from interest income on loans and debt securities.
Incannex Healthcare Inc is a clinical-stage biopharmaceutical development company dedicated to developing inventive medicines for patients living with serious chronic diseases and unmet needs. The Company's drug candidates include IHL-42X for the treatment of obstructive sleep apnea (OSA) and PSX-001, the Company's psilocybin treatment in combination with psychological therapy in development to treat patients with generalized anxiety disorder (GAD). The Company also has a drug candidate, IHL-675A, for the treatment of rheumatoid arthritis. Each of these programs target conditions that currently have limited, inadequate, or no approved pharmaceutical treatment options. The Company continues to evaluate strategies for IHL-675A when and as resources permit.